Hepatitis C virus (HCV) is a prevalent and globally distributed human pathogen that currently infects an estimated 170 million people. Chronic HCV infection significantly increases the risk of chronic hepatitis. The virus exhibits a very high degree of genetic diversity that is classified six genotypes and sub-classified more than 80 subtypes by phylogenetic analysis. The various genotypes and subtypes of HCV have been associated with different epidemiological and geographical spread patterns. Genotypes 1 and 2 are globally distributed; genotype 3 is predominant in Asia, North America and parts of Europe; similar regional patterns of endemic diversity have been found for genotype 4 in Europe, Middle East and Central Africa, for genotype 5 in parts of Africa and Europe, and for genotype 6 in Southeast Asia and North America. Up to date, four HCV genotypes, including genotype 1, 2, 3 and 6, were identified in China. Genotypes 1b and 2a were mainly found in Northern China. The fast spreading of genotypes 3 and 6 in Southern and South-Western China was reported by recent studies. It’s deduced that Yunnan may become an important source of HCV epidemic and spread, which will cause great changes in the distribution of HCV genotypes and subtypes, and a variety of transmission. With the development of evolution theory and related analysis methods, such as coalescent theory and evolutionary molecular, it is possible to understand the characters of virus evolution and migration. For HCV, the further understanding on the prevalence and evolution characters of various genotypes is very important for the deep investigation of HCV epidemic and the develop-ment of prevention strategy.
[1] Centers for Disease Control and Prevention(CDC). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV related chronic disease. MMWR Recomm Rep, 1998, 47(RR19): 1-39.
[2] Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med, 2001, 345(1): 41-52.
[3] Williams R. Global challenges in liver disease. Hepatology, 2006, 44(3): 521-526.
[4] Chen YD, Liu MY, Yu WL, Li JQ, Peng M, Dai Q, Liu X, Zhou ZQ. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreat Dis Int, 2002, 1(2): 194-201.
[5] Xia X, Luo J, Bai JL, Yu RB. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health, 2008, 122(10): 990-1003.
[6] Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J Virol, 1992, 66(3): 1476-1483.
[7] Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science, 1998, 282(5386): 103-107.
[8] Kang SM, Choi SH, Park CY, Kim MH, Kim TK, Park JM, Koh MS, Kang HJ, Hwang SB. Monoclonal antibody recognizing N-terminal epitope of hepatitis C virus nonstructural 5B inhibits viral RNA replication. J Viral Hepat, 2008, 15(4): 305-313.
[9] 张中林, 山松, 陈曦, 苏宁, 吴祥甫, 钱凯先, 沈桂芳. 丙肝病毒融合抗原基因NS3-C定点整合入衣藻叶绿体基因组的研究. 遗传, 1999, 21(6): 1-173.
[10] Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol, 1993, 74(Pt11): 2391-2399.
[11] Murphy DG, Willems B, Deschênes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol, 2007, 45(4): 1102-1112.
[12] Simmonds P. Genetic diversity and evolution of hepatitis C virus 15-years on. J Gen Virol, 2004, 85(Pt11): 3173-3188.
[13] Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology, 1997, 25(6): 1527-1538.
[14] Pybus OG, Markov PV, Wu A, Tatem AJ. Investigating the endemic transmission of the hepatitis C virus. Int J Parasitol, 2007, 37(8-9): 839-849.
[15] Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics, 21(3): 379-384.
[16] Kryczka W, Brojer E, Zarebska-Michaluk D, Medyńska J, Urbaniak A. Factors influencing natural history of chronic hepatitis C. Med Sci Monit, 2001, (Suppl. 1): 212-216.
[17] Nakano I, Fukuda Y, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Kumada T, Nakano S. Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype. Gut, 2001, 49(2): 263-267.
[18] Nakano T, Lu L, Liu P, Pybus OG. Viral gene sequences reveal the variable history of hepatitis C virus infection among countries. J Infect Dis, 2004, 190(6): 1098-1108.
[19] Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol, 2007, 7: 214.
[20] 敖雁, 朱明星, 徐辰武. 贝叶斯统计在QTL作图中的应用研究进展. 遗传, 2007, 29(6): 668-674.
[21] Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SY, Shapiro B, Pybus OG, Allain JP, Hatzakis A. The global spread of hepatitis C virus 1a and 1b: A phylodynamic and phylogeographic analysis. PLoS Med, 2009, 6(12): e1000198.
[22] Courtwright D. Dark paradise: a history of opiate addiction in America. Cambridge: Harvard University Press, 2001.
[23] Stimson GV. The global diffusion of injecting drug use: implications for human immunodeficiency virus infection. Bull Narc, 1993, 45(1): 3-17.<
